Mundipharma’s rezafungin cleared by MHRA for invasive candidiasis in Great Britain
In a significant advancement for antifungal therapy, Napp Pharmaceuticals Limited, a key player within the international network of Mundipharma independent associated companies, has announced the authorization of Rezafungin by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of invasive candidiasis in adults in Great Britain. This approval is a testament to the […]